Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment strateg...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | Urology Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214442019301974 |